What Does Stifel Think About Inspire Medical (INSP) After a Guidance Cut That Surprised Wall Street?

What Does Stifel Think About Inspire Medical (INSP) After a Guidance Cut That Surprised Wall Street? Abdul Rahman Wed, May 27, 2026 at 11:56 PM GMT+2 2 min read INSP SF Inspire Medical Systems, Inc. (NYSE: INSP ) is one of the best medical technology stocks to buy right now .

On May 5, Stifel analyst Jonathan Block lowered his price target on Inspire Medical Systems, Inc. (NYSE:INSP) to $65 from $70, while keeping his Buy rating. Block made the call in reaction to Inspire’s weaker-than-expected guidance shared in the Q1 2026 earnings.

What Does Stifel Think About Inspire Medical (INSP) After a Guidance Cut That Surprised Wall Street? Copyright: lenetstan / 123RF Stock Photo Inspire reported quarterly revenue of $204. 6 million and an adjusted diluted earnings per share of $0.

10. Both of these figures were ahead of Wall Street estimates, but their impact was drowned out by management slashing the company’s full-year 2026 revenue outlook to the $825 million-$875 million range. Stifel had anticipated a guidance of no less than $900 million, and even so, this was the lowest estimate on Wall Street.

The consensus estimate on the Street was $966 million. Management attributed the guidance reduction to a billing and payment problem tied to how Inspire’s implantable sleep apnea device, which is a hypoglossal nerve stimulator (HGNS), is now being coded for insurance reimbursement. Starting January 1 this year, the Centers for Medicare & Medicaid Services (CMS) introduced six new billing codes for HGNS procedures, and the way one of these codes is being applied has made doctors significantly less willing to perform the procedure.

Nonetheless, Block noted that Inspire’s dominance in the HGNS market remains intact, and reimbursement clarity should improve. Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company that develops and commercializes minimally invasive solutions for obstructive sleep apnea.

Its primary product, the Inspire therapy system, is an implantable neurostimulation device designed to treat sleep apnea. While we acknowledge the potential of INSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the   best short-term AI stock .

READ NEXT:  7 Best Augmented Reality Penny Stocks to Buy and 10 Best Gene Therapy Stocks to Buy in 2026 . Disclosure: None. Follow Insider Monkey on Google News .